Turja Chakrabarti

Assistant Professor

Dr. Chakrabarti serves as faculty within the UCSF Division of Hospital Medicine, with a primary clinical role on the Hematology-Oncology-BMT Hospitalist Service.

His research interests focus on novel therapies for lung cancer. Specifically, he is investigating mechanisms to overcome resistance to targeted therapies in patients with oncogene mutations in lung cancer such as EGFR.

In addition, he is the President & Founder of Pratit International, an organization dedicated to bridging global health disparities with a special focus on vulnerable communities in Kolkata, India.
Education
06/2021 - Internal Medicine Chief Residency, Johns Hopkins Bayview Medical Center
06/2020 - Internal Medicine Residency, Johns Hopkins Bayview Medical Center
MD, 05/2017 - Doctor of Medicine, Eastern Virginia Medical School
MS, 05/2013 - Physiology & Biophysics, Georgetown University
BA, 05/2012 - Global Health & Societies, University of Pennsylvania
Honors and Awards
  • Alpha Omega Alpha Medical Honor Society, Johns Hopkins University School of Medicine, 2020
  • Larry Waterbury MD Award for resident clinical excellence, Johns Hopkins University School of Medicine, 2020
  • Gold Humanism Honor Society, Eastern Virginia Medical School, 2016
Publications

  1. Hobor S, Al Bakir M, Hiley CT, Skrzypski M, Frankell AM, Bakker B, Watkins TBK, Markovets A, Dry JR, Brown AP, van der Aart J, van den Bos H, Spierings D, Oukrif D, Novelli M, Chakrabarti T, Rabinowitz AH, Ait Hassou L, Litière S, Kerr DL, Tan L, Kelly G, Moore DA, Renshaw MJ, Venkatesan S, Hill W, Huebner A, Martínez-Ruiz C, Black JRM, Wu W, Angelova M, McGranahan N, Downward J, Chmielecki J, Barrett C, Litchfield K, Chew SK, Blakely CM, de Bruin EC, Foijer F, Vousden KH, Bivona TG, TRACERx consortium, Hynds RE, Kanu N, Zaccaria S, Grönroos E, Swanton C. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature communications. 2024. PMID: 38871738


  2. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer discovery. 2023. PMID: 37068173


  3. Friedes C, Chakrabarti T, Olson S, Prichett L, Brahmer JR, Forde PM, Voong RK, Marrone KA, Lam VK, Hann CL, Broderick SR, Battafarano RJ, Ha JS, Bush EL, Yang SC, Hales RK, Feliciano JL. Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy. Lung cancer (Amsterdam, Netherlands). 2021. PMID: 33611224